Metrics to compare | KZR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKZRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −9.0x | −0.5x | |
PEG Ratio | −0.03 | −0.26 | 0.00 | |
Price/Book | 0.8x | 5.3x | 2.6x | |
Price / LTM Sales | - | 7.6x | 3.2x | |
Upside (Analyst Target) | −17.9% | 120.4% | 50.8% | |
Fair Value Upside | Unlock | 2.7% | 7.7% | Unlock |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.